Protein S: Nursing Guide
Protein S is a vitamin K–dependent plasma cofactor that lets activated protein C inactivate factors Va and VIIIa — central to thrombophilia screening after venous thromboembolism. Nurses protect result validity with citrate collection filled to the line, warfarin and acute-VTE timing, and clinical escalation when new leg swelling or chest pain develops — not while waiting for send-out coagulation results.
Contents
Quick Facts
Key Takeaway
Low free protein S raises lifetime venous thromboembolism risk but does not diagnose an active clot today — and acute thrombosis, warfarin, pregnancy, oestrogen therapy, and inflammation can temporarily lower levels until.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
Light blue top
3.2% sodium citrate (9:1 blood-to-anticoagulant ratio)
Platelet-poor plasma (citrated)
Tube filled to completion per coagulation protocol; follow laboratory minimum volume for platelet-poor plasma
After acute venous thromboembolism is treated and the patient is clinically stable; not during active anticoagulant therapy per NHS and ISTH thrombophilia guidance — follow local policy for warfarin hold interval
No test preparation is usually required
Double-centrifuge to platelet-poor plasma, aliquot to plastic vial, freeze per institutional coagulation handling — not routine room-temperature transport
Typically days (referral coagulation laboratory)
Coagulation / specialized hemostasis laboratory
What is Protein S?
Protein S measures free protein S antigen (and total protein S when ordered) in platelet-poor plasma. Protein S is synthesized in the liver, requires vitamin K, and serves as the essential cofactor for activated protein C — the enzyme that slows thrombin generation by degrading activated factors V and VIII.
Overview
Nurses most often support protein S testing during thrombophilia panels after unexplained deep vein thrombosis, pulmonary embolism, unusual-site venous thrombosis, or family history of protein S deficiency. Free antigen assay is commonly the first step; total antigen and repeat sampling help distinguish Type I quantitative deficiency from Type III low free with normal total — the pattern often seen with pregnancy, oral contraceptives, or acute illness.
Because protein S is consumed during acute thrombosis and lowered by warfarin, liver disease, pregnancy, oral contraceptives, hormone replacement therapy, nephrotic syndrome, and inflammation, results must be interpreted with timing and medication history. Repeat testing after recovery and off interfering anticoagulants is commonly required before confirming lifelong hereditary deficiency per ISTH 2021 laboratory guidance and ASH 2023 thrombophilia recommendations.
Before collection, confirm the indication matches thrombophilia protocol timing, verify the patient is not actively clotting on heparin-contaminated lines, use a completely filled citrate tube with gentle mixing, and document recent VTE, warfarin or other anticoagulants, pregnancy, oestrogen therapy, and liver or kidney disease. Escalate new or worsening leg swelling, chest pain, or shortness of breath according to facility policy — do not wait for the send-out result.
Protein S Timing, Warfarin, and Specimen Safety
Protein S results guide long-term thrombosis risk conversations, but warfarin, acute VTE, pregnancy, and poor citrate technique can falsely lower free antigen and trigger unnecessary lifelong labels. Never delay assessment of new leg swelling, chest pain, or dyspnoea while waiting for send-out coagulation results.
- Acute VTE symptoms with pending or low protein S — escalate clinically first
- Testing during acute clot, on warfarin, or with underfilled citrate tube without repeat plan
- Interpreting a single low free antigen as confirmed hereditary deficiency without free/total comparison and repeat sampling
- Starting or stopping warfarin around unconfirmed low protein S without haematology input
Document: indication and timing criteria met, tube fill and processing, warfarin and anticoagulant holds, clinical VTE symptoms, result with reference interval, notifications, and repeat or genetics plan.
What Protein S Can and Cannot Tell You
This test can help identify:
- Reduced free protein S suggesting Type I, II, or III patterns when appropriately timed
- Acquired lowering from pregnancy, oral contraceptives, HRT, inflammation, or recent thrombosis
- Warfarin-related transient reduction requiring repeat testing off vitamin K antagonists
- Need for free/total comparison, repeat sampling, or genetics after a confirmed low result
This test cannot:
- Diagnose acute deep vein thrombosis or pulmonary embolism by itself — use acute VTE pathways
- Replace clinical assessment, imaging, or D-dimer protocols where indicated
- Confirm hereditary deficiency from one sample during acute illness or on warfarin
- Determine anticoagulation duration or hormone choices alone — requires specialist decisions
Warfarin Holds and Citrate Validity Before Protein S Draw
Verify
Clarify before proceeding when:
- Order is routine on acute admission without thrombophilia timing criteria
- Patient still on warfarin, heparin, or DOAC without authorized hold window
- Prior specimen rejected for underfill, hemolysis, or clot
- Active unilateral leg swelling, chest pain, or dyspnoea is present
- Pregnant or on oestrogen therapy without clinical context on the requisition
- Central line draw may contain heparin flush and policy requires peripheral draw
- Result conflicts with strong family history but sample timing was during acute PE only
Free vs Total Antigen and Type I–III Patterns
Pair free protein S with timing after VTE, warfarin holds, total antigen results, pregnancy or oestrogen status, and current symptoms. ISTH 2021 guidance emphasizes free antigen as the primary screening assay; repeat testing after recovery and off interfering drugs is commonly required before confirming hereditary deficiency.
| Clinical context | Free vs total pattern | Nursing focus |
|---|---|---|
| Type I quantitative deficiency | Low free and low total antigen | Support genetics referral and family screening per haematology |
| Type II qualitative (rare) | Low function with normal antigen — specialist assay | Do not reassure based on antigen alone; await haematology interpretation |
| Type III acquired pattern (common) | Low free with normal total | Document pregnancy, OCP/HRT, inflammation; repeat when clinically appropriate |
| Recent warfarin therapy | Transiently low free protein S possible | Document hold interval; repeat when off vitamin K antagonists per protocol |
Protein S in Thrombophilia Workflow
Diagnostic safety badge: Routine diagnostic test — standard identification, preparation, and result-follow-up checks still apply; low results may require confirmatory free/total testing and specialist follow-up.
Check-before-test protocol
- Identity + indication + thrombophilia timing criteria (post-VTE, off warfarin per policy)
- Warfarin and anticoagulant hold authorized and documented
- Citrated tube supply and processing steps confirmed
- Clinical VTE symptom screen
- Requisition clinical history completed (pregnancy, OCP/HRT, liver disease)
Critical teach-back questions
- “Can you tell me why we are checking your protein S level now rather than during your hospital clot treatment?”
- “What new leg or chest symptoms should you report before the result comes back?”
- “Why might the team repeat this blood test after you finish warfarin?”
Care coordination: prescriber, haematology, laboratory/coagulation services, genetics service when indicated, anticoagulation clinic, and rapid response per institutional protocol.
Why Protein S is Ordered
Protein S testing is ordered when clinicians evaluate inherited or acquired protein S deficiency as part of a hypercoagulability workup — typically after VTE is treated and the patient is stable, not as a routine screen for every clot.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Unexplained venous thromboembolism in a relatively young patient | Is a high-risk thrombophilia such as protein S deficiency present? | Part of thrombophilia screening after appropriately timed sampling when results may change long-term anticoagulation or prophylaxis decisions per ASH 2023 guidance. |
| Family history of protein S or protein C deficiency | Does selective family screening apply per haematology or genetics protocol? | Relatives may be tested when a severe deficiency or very early VTE occurred in the family — not as routine population screening per reviewed references. |
| Recurrent venous thromboembolism despite anticoagulation | Could an underlying natural anticoagulant defect explain recurrence? | Protein S deficiency is among inherited thrombophilias associated with elevated VTE risk when appropriately confirmed off anticoagulants and acute illness. |
| Unusual-site venous thrombosis (cerebral, splanchnic, renal veins) | Should long-term management consider severe thrombophilia? | Selected scenarios support thrombophilia evaluation when results may influence duration of anticoagulation or hormone-therapy counseling. |
Contraindications and Precautions
There is no absolute laboratory contraindication, but nurses must not proceed with routine thrombophilia sampling when timing or specimen integrity would produce misleading results.
- Active acute thrombosis or recent VTE treatment without protocol delay — protein S may be consumptively low.
- Ongoing warfarin, heparin, or direct oral anticoagulant without authorized hold per laboratory policy.
- Underfilled citrate tube, hemolyzed sample, or failure to obtain platelet-poor plasma.
- Pregnancy, oral contraceptives, hormone replacement therapy, liver disease, DIC, nephrotic syndrome, and acute inflammation commonly lower free protein S.
- Warfarin and other vitamin K antagonists reduce protein S along with other vitamin K–dependent proteins per ISTH 2021 recommendations.
- A single borderline low free antigen should prompt repeat testing after recovery, not immediate lifelong diagnosis without free/total comparison and confirmation.
- New or worsening unilateral leg swelling, pain, warmth, or redness while awaiting results.
- Acute chest pain, dyspnoea, tachycardia, or hypoxia suggesting pulmonary embolism.
- Confirmed very low protein S with acute thrombosis signs — notify prescriber and haematology per protocol; evaluate outcomes of anticoagulation plan.
Patient Preparation
No special patient preparation is usually required for protein S testing per NHS laboratory sources, but thrombophilia protocols require specific timing relative to acute clots, warfarin, and other anticoagulants.
Pre-test checksReview warfarin and other vitamin K antagonists, unfractionated heparin, low-molecular-weight heparin, direct oral anticoagulants, oral contraceptives, and hormone replacement therapy. Do not stop prescribed anticoagulation without prescriber authorization — clarify hold timing with the ordering clinician and laboratory.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Protein S. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
Free protein S antigen is commonly reported in IU/mL or as a percentage of the laboratory reference population; total protein S may be reported when ordered. Decreased free antigen suggests deficiency or acquired lowering; comparison of free and total antigen helps distinguish Type I, II, and III patterns per ISTH 2021 guidance.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Within expected range or therapeutic target | Within institutional reference interval (free or total antigen) | Protein S level adequate at time of sample | If part of thrombophilia panel, interpret with other results; hereditary deficiency unlikely if appropriately timed free antigen is normal |
| Near therapeutic target / borderline | Borderline low or discordant free vs total antigen | May reflect assay variation, pre-analytic error, warfarin effect, pregnancy, or evolving acquired state | Recommend repeat testing per haematology protocol after appropriate interval and medication review |
| Prolonged / above target | Elevated protein S antigen | Not usually clinically significant when free and total are concordant per reviewed references | Interpret with clinical context; not a typical thrombosis escalation trigger alone |
| Shortened / below target | Below reference interval (decreased free or total antigen) | Possible Type I, II, or III deficiency pattern, acquired consumption, warfarin effect, pregnancy, or oestrogen-associated lowering | Notify prescriber; arrange free/total comparison and repeat testing off anticoagulants per protocol; genetics referral if confirmed |
Protocol targets, critical results and escalation
Universal numeric critical values for protein S are Turnaround and screening rules vary by institution; follow local institutional policy (ISTH 2021, NHS laboratory sources, ASH 2023). Escalation is driven by clinical thrombosis symptoms, confirmed severe deficiency with VTE signs, and need for specialist follow-up — not a single laboratory panic threshold.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Low protein S with acute VTE signs | Decreased free antigen plus new leg swelling, chest pain, or dyspnoea | Escalate according to facility policy; initiate acute VTE pathway per prescriber — do not delay for send-out results |
| Confirmed hereditary deficiency with new thrombosis | Very low confirmed free protein S with symptomatic VTE | Notify prescriber and haematology; evaluate anticoagulation plan and family screening per protocol |
| Specimen rejected / invalid | Hemolysis, clot, underfill, or heparin contamination | Repeat collection per coagulation policy before thrombophilia conclusions are made |
Stop routine workflow and escalate according to facility policy when the patient develops symptoms suggesting acute venous thromboembolism, when results conflict strongly with the clinical picture, or when a critically ill patient needs immediate VTE assessment — regardless of pending protein S results.
Factors Affecting Results
Protein S assays are sensitive to pre-analytic variables, warfarin, pregnancy, and concurrent illness. Nurses prevent misinterpretation by correct citrate technique and documenting clinical context.
- Falsely low free antigen during acute thrombosis, surgery, pregnancy, or inflammation
- Warfarin or vitamin K antagonist effect lowering protein S at time of draw
- Underfilled citrate tube altering anticoagulant ratio
- Type III pattern with low free but normal total misread as “normal” if only total is reviewed
- Single test during intercurrent illness or on oestrogen therapy without repeat confirmation
- Assuming normal free antigen rules out all thrombophilia — other defects may coexist
- Timing relative to acute VTE, warfarin, and anticoagulant therapy
- Pregnancy, oral contraceptives, HRT, liver disease, nephrotic syndrome
- Specimen quality — hemolysis, platelets, delayed processing
Protein S testing alone does not diagnose active thrombosis and cannot replace clinical probability assessment. ASH 2023 generally recommends against broad thrombophilia testing in many VTE scenarios; nurses support appropriate ordering and timing rather than routine panels on every clot. Reference ranges, assay methods (free vs total), and repeat intervals vary by laboratory.
Nursing Responsibilities
Nursing responsibilities emphasize correct coagulation specimen handling, warfarin and timing documentation, symptomatic monitoring while results are pending, and clear communication of low or unexpected values.
Before the TestDocumentation
Documentation should link specimen quality, clinical context, and communication of abnormal results.
“Free protein S specimen collected 10:15 — light-blue citrate tube filled to line, inverted ×6, double-spun per lab policy, frozen aliquot to coagulation lab. Patient 10 weeks post-PE treatment; warfarin held 6 weeks per haematology. No acute leg pain today. Requisition notes family history of protein S deficiency. Result pending; patient taught repeat free/total testing may be needed.”
- Indication, order date, and thrombophilia protocol timing met (yes/no)
- Tube type, fill level, mixing, processing, and transport compliance
- Recent VTE, pregnancy, oestrogen therapy, warfarin hold, and liver/renal disease
- Result value with laboratory reference interval and flag status
- Prescriber/haematology notification and patient teaching provided
- Repeat specimen plan and genetics referral if ordered
Patient and Family Education
Patients often worry that a blood test predicts an immediate clot. Use clear, calm language about what protein S measures and why warfarin timing matters.
Protein S NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Protein S safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Free protein S antigen — plasma, thrombophilia panel
- Indication: 32-year-old with prior pulmonary embolism; family history of protein S deficiency
- Timing: Ordered today — 10 weeks after completing initial anticoagulation; warfarin held per haematology
- Related orders: Protein C, antithrombin III, lupus anticoagulant screen; factor V Leiden per protocol
- Result: Free protein S 0.52 IU/mL (below laboratory reference); prior draw during acute PE was 0.41 IU/mL
- Trend / prior value: Improved from acute phase but still below reference; total protein S antigen pending
- Pending tests: Total protein S antigen, genetics referral discussion, repeat free antigen if hold window completed
- Vital signs: HR 76/min, BP 118/70, RR 16/min, SpO₂ 98% on room air, temp 36.8°C
- Symptoms: No current leg pain or dyspnoea; mild anxiety about “blood clot gene”
- Focused assessment: Calves symmetric, no tenderness; lungs clear; warfarin held 6 weeks per haematology order
- Preparation notes: Citrated tube filled to line; patient asked why test was not done during hospital admission
- Collection events: Previous sample rejected for underfilled citrate tube; today’s specimen accepted
- Teaching gaps / safety concerns: Low free antigen not yet confirmed hereditary; patient unclear on when to report symptoms; pending total antigen
Answer key & rationale
Frequently Asked Questions
FAQ
Why is protein S tested after a blood clot instead of during the acute admission?
Acute thrombosis consumes protein S and anticoagulant therapy — especially warfarin — interferes with interpretation. NHS thrombophilia guidance and ISTH 2021 recommendations support testing when the patient is stable, after VTE is treated, and off interfering anticoagulants — follow local policy for hold intervals.
Does the patient need to fast before protein S testing?
No test preparation is usually required per reviewed NHS laboratory sources. Follow fasting instructions only if other ordered tests on the same draw require it.
What does a low free protein S result mean?
It suggests reduced protein S, which may reflect inherited Type I deficiency, rare Type II dysfunctional protein, common Type III low free with normal total (pregnancy, OCP, inflammation), warfarin effect, or recent thrombosis. Free/total comparison and repeat sampling help clarify. It does not by itself prove an active clot today.
Can warfarin affect protein S results?
Yes. Warfarin lowers protein S along with other vitamin K–dependent proteins. Testing is usually deferred until anticoagulant therapy is completed per thrombophilia protocol — do not stop prescribed warfarin without prescriber authorization.
Is protein S testing recommended for every patient with one DVT or PE?
Not routinely. ASH 2023 guidelines conditionally recommend against broad thrombophilia testing in many VTE scenarios and support selective testing when results would change management — such as strong family history of protein S deficiency.
What tube is used for protein S antigen testing?
Platelet-poor plasma from a light-blue-top tube with 3.2% sodium citrate, filled to the marked line, with gentle mixing and laboratory processing per coagulation protocol (often double-centrifuged and frozen for send-out testing per Leeds, NBT, and NW London NHS laboratory guidance).
When should nurses escalate before the result returns?
Escalate according to facility policy if the patient develops new unilateral leg swelling, pain, warmth, redness, chest pain, dyspnoea, tachycardia, or hypoxia — these may indicate acute VTE regardless of pending protein S results.
References
References
-
Marlar RA; et al. Recommendations for laboratory testing for protein S deficiency. J Thromb Haemost. 2021; SSC of the ISTH.https://onlinelibrary.wiley.com/doi/10.1111/jth.15109
-
North West London Pathology. Protein C / Protein S. London: NWLP.https://www.nwlpathology.nhs.uk/test/protein-c-protein-s/
-
Leeds Teaching Hospitals NHS Trust. Protein S (part of thrombophilia screen).https://www.leedsth.nhs.uk/services/pathology/tests/protein-s-part-of-thrombophilia-screen/
-
University of Chicago Medicine Laboratories. Protein S Activity, Free Antigen (FPSB).https://uchicagomedlabs.testcatalog.org/show/FPSB
-
American Society of Hematology. 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023.https://pmc.ncbi.nlm.nih.gov/articles/PMC10709681/
-
Kujovich JL. Hypercoagulability. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.https://www.ncbi.nlm.nih.gov/books/NBK538251/
-
North Bristol NHS Trust. Protein S. Severn Pathology.https://www.nbt.nhs.uk/severn-pathology/requesting/test-information/protein-s
-
Stevens SM; et al. Hypercoagulable states: an algorithmic approach to laboratory testing. Blood Rev. 2016.https://pmc.ncbi.nlm.nih.gov/articles/PMC4090343/
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Protein S.
Policies: Medical Review Process · Editorial Policy · Correction Policy